Cargando…
ASO Author Reflections: Objective Response Rate after Short Duration (< 9 Weeks) Is Not Inferior to Moderate (9–27 Weeks) or Long Duration (> 27 Weeks) of Neoadjuvant Endocrine Therapy (NET)—An NCDB Analysis
Autores principales: | Burkbauer, Laura, Goldbach, Macy M., Tchou, Julia C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310403/ https://www.ncbi.nlm.nih.gov/pubmed/34304315 http://dx.doi.org/10.1245/s10434-021-10517-w |
Ejemplares similares
-
ASO Visual Abstract: Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016)
por: Goldbach, Macy M., et al.
Publicado: (2021) -
Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016)
por: Goldbach, Macy M., et al.
Publicado: (2021) -
Correction to: Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016)
por: Goldbach, Macy M., et al.
Publicado: (2021) -
ASO Author Reflections: Neoadjuvant Endocrine Therapy: A Pill in Time Saves Nine
por: Williams, Austin D., et al.
Publicado: (2022) -
ASO Author Reflections: Right Sizing Axillary Surgery in Patients treated with Neoadjuvant Endocrine Therapy
por: Hieken, Tina J., et al.
Publicado: (2021)